Murphy Usa Inc
Change company Symbol lookup
Select an option...
MUSA Murphy Usa Inc
SCL Stepan Co
GRWG GrowGeneration Corp
ROG Rogers Corp
ALB Albemarle Corp
DD Dupont De Nemours Inc
SMG Scotts Miracle-Gro Co
MTX Minerals Technologies Inc
HUN Huntsman Corp
PPG PPG Industries Inc
Go

Consumer Discretionary : Specialty Retail | Mid Cap Blend
Company profile

Murphy USA Inc. is engaged in the marketing of retail motor fuel products and merchandise through a chain of retail stores. It markets refined products through a network of retail gasoline stores and to unbranded wholesale customers. It also operates non-fuel convenience stores in the northeast of United States. Its business also includes certain product supply and wholesale assets, including product distribution terminals and pipeline positions. Its retail stores under the brand name Murphy USA participate in the Walmart discount program. The Walmart discount program offers a cents-off per gallon purchased for fuel when using specific payment methods as decided by Walmart and the Company. Its retail stores are located in approximately 27 states, primarily in the Southeast, Southwest and Midwest United States. It has a total of approximately 1,679 Company stores of which 1,151 are Murphy USA, 370 are Murphy Express and 158 are QuickChek.

Closing Price
$292.40
Day's Change
3.60 (1.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
295.44
Day's Low
288.85
Volume
(Light)
Volume:
96,247

10-day average volume:
276,115
96,247

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline

7:30 am ET September 21, 2022 (PR Newswire) Print

Fifth Milestone Achieved by HemoShear with Novel Compounds for Second Target

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive drug discovery agreement established in January 2019.

By combining Horizon's expertise in gout with HemoShear's drug discovery capabilities, we are breaking new ground

"In three years, HemoShear has identified two novel therapeutic targets and generated lead compounds for these two completely different strategies to potentially treat gout," said Robert Stoffel, PhD, vice president, research at Horizon. "Gout is often associated with elevated uric acid levels and data from the REVEAL-Tx(TM) platform indicates that these programs have the potential to lower uric acid levels. We look forward to the ongoing work on potential candidates selective to a second target."

"By combining Horizon's expertise in gout with HemoShear's drug discovery capabilities, we are breaking new ground with the early stage characterization of two novel potential approaches to lowering uric acid levels," said Ryan Feaver, PhD, executive director and head of exploratory biology at HemoShear. "Our REVEAL-Tx(TM) drug discovery platform has been a key factor in achieving this milestone and in the success of the collaboration, aimed at delivering first-in-class modulators for both programs."

Under the terms of the agreement, HemoShear received an upfront payment and R&D funding, and Horizon received exclusive access to HemoShear's proprietary disease modeling platform, to discover potential new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon would make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed.

Gout is a chronic, progressive inflammatory form of arthritis affecting more than nine million people in the United States that is caused by excess uric acid in the body and needs to be managed aggressively. If uric acid levels in the blood remain elevated, crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling and joint damage. In addition to the joint damage, urate crystals can also deposit in other organs of the body, and if left unmanaged, gout can lead to significant tissue damage. Uncontrolled gout occurs when people living with gout continue to have high levels of uric acid and gout symptoms despite the use of standard oral urate-lowering therapies.

About HemoShear Therapeutics

HemoShear Therapeutics, Inc. is a privately held clinical stage company developing treatments for rare diseases with significant unmet patient need. HemoShear's drug discovery platform, REVEAL-Tx(TM), enables the Company's scientists to create best-in-class, biologically relevant human disease models to uncover the underlying mechanisms of disease, translate those discoveries into drug targets, and select candidates that may treat patients successfully. HemoShear completed an exclusive partnership identifying two novel therapeutic approaches in nonalcoholic steatohepatitis (NASH) for Takeda in 2021. The Company has ongoing collaborations with Takeda in a rare liver disease and with Horizon Therapeutics in gout. For more information visit www.HemoShear.com.

https://c212.net/c/img/favicon.png?sn=CL79039&sd=2022-09-21

View original content:https://www.prnewswire.com/news-releases/hemoshear-therapeutics-advancing-novel-modulators-against-second-target-for-horizon-therapeutics-gout-discovery-pipeline-301628941.html

SOURCE HemoShear Therapeutics

https://rt.prnewswire.com/rt.gif?NewsItemId=CL79039&Transmission_Id=202209210730PR_NEWS_USPR_____CL79039&DateId=20220921

comtex tracking

COMTEX_414953450/1005/2022-09-21T07:30:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.